January 22, 2014

Bayer successfully issued three Eurobonds with a combined volume of €2 billion (US$2.7 billion) to be used for general corporate purposes and possible acquisitions.

All the tranches were placed on attractive terms. The €500 million (US$678 million) two-year floating-rate Eurobond was issued at an interest rate of 22 basis points over three-month Euribor. The €750 million (US$1 million) four-year fixed-rate Eurobond carries a coupon of 1.125%, and the €750 million (US$1 million) seven-year fixed-rate Eurobond carries a coupon of 1.875%. The issuances met with exceptionally high demand on the capital market and the order book was over four times oversubscribed.

Werner Baumann, CFO of Bayer AG said: "The successful placement of these benchmark bonds confirms Bayer's high standing on the capital market. We have used our strong position as an issuer and the positive market environment to improve our debt and liquidity structure."

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. It sets trends in research-intensive areas and its products and services are designed to benefit people and improve their quality of life.